GENE ONLINE|News &
Opinion
Blog

2018-05-29|

May 29, 1943: Luria-Delbrück Experiment Published Proving Random Mutations in Bacteria

by GeneOnline
Share To

On May 29, 1943, Italian-American geneticists Salvador Luria and Max Delbrück published the results of the Luria-Delbrück experiment (also known as the Fluctuation Test), demonstrating that the gene mutations in bacteria occur spontaneously and randomly. The experiment shown that, in bacteria, genetic mutations arise in the absence of selection, rather than being a response to selection. Which discovery significantly helped scientists further understand DNA replication and genetic evolution in bacteria, and proved that Darwin’s theory of natural selection acting on random mutations applies to bacteria as well as to other complex organisms. Together with Alfred Hershey, Salvador Luria and Max Delbrück won the 1969 Nobel Prize in Physiology or Medicine for this work.

Reference
https://en.wikipedia.org/wiki/Luria%E2%80%93Delbr%C3%BCck_experiment

Image Source
http://www.discoveryandinnovation.com/BIOL202/notes/lecture15.html

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Biotech in Beauty: Engineered Skin Bacteria Designed To Treat Acne
2024-05-10
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
R&D
Vaccine Development Has No Limits, the Application Direction of mRNA After the Nobel Prize
2023-10-17
LATEST
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
TCELS’s Path to a Self-Sufficient Biotech Thailand: Entrepreneurs in Global Competitiveness, Raw Material Exports, and Cosmetic Innovations
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development
2024-09-26
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top